Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603

Watchlist Manager
Shijiazhuang Yiling Pharmaceutical Co Ltd Logo
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Watchlist
Price: 16.04 CNY -1.05%
Market Cap: 26.8B CNY
Have any thoughts about
Shijiazhuang Yiling Pharmaceutical Co Ltd?
Write Note

Shijiazhuang Yiling Pharmaceutical Co Ltd
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shijiazhuang Yiling Pharmaceutical Co Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Deferred Income Tax
ÂĄ128.9m
CAGR 3-Years
355%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Deferred Income Tax
ÂĄ255m
CAGR 3-Years
28%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Deferred Income Tax
ÂĄ22.5m
CAGR 3-Years
-23%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Deferred Income Tax
ÂĄ85.1m
CAGR 3-Years
65%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Deferred Income Tax
ÂĄ91.3m
CAGR 3-Years
18%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shijiazhuang Yiling Pharmaceutical Co Ltd
Glance View

Market Cap
26.8B CNY
Industry
Pharmaceuticals

Shijiazhuang Yiling Pharmaceutical Co Ltd, rooted in the northern heart of China, embodies a harmonious blend of traditional Chinese medicine and modern pharmaceutical science. Born from the insightful vision of Wu Yiling, a prominent figure in integrating traditional Chinese medical practices with contemporary research methodologies, the company has grown into a significant player in the healthcare sector. Its foundation is deeply entrenched in leveraging ancient herbal wisdom while adopting cutting-edge biopharmaceutical technologies. At the core of its operations, Yiling Pharmaceutical specializes in the research, development, and production of therapeutic drugs aimed at treating chronic diseases and boosting immunity. This dual approach allows the company to carve out a niche in producing signature products like Lianhua Qingwen, a respiratory treatment renowned for its efficacy in alleviating symptoms from colds and flu. What powers Yiling Pharmaceutical's continued growth is its steadfast commitment to research and development, translated into a structured pipeline of innovative drugs. The company's funding funnel directs substantial resources into ongoing research, ensuring a constant expansion and refinement of their product portfolio. With an emphasis on effectiveness backed by rigorous scientific validation, Yiling has successfully navigated the complexities of pharmaceutical regulations, extending its reach beyond domestic borders to international markets. This expansionist strategy, coupled with a deep understanding of traditional medicine, forms a robust revenue stream, encapsulating both the domestic market's demand for traditional therapies and the international community's growing interest in alternative medicine solutions. Through these channels, Yiling harmonizes its traditional roots with a forward-thinking business model, ensuring steady financial footholds and promising horizons.

Intrinsic Value
19.51 CNY
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Deferred Income Tax?
Deferred Income Tax
128.9m CNY

Based on the financial report for Sep 30, 2024, Shijiazhuang Yiling Pharmaceutical Co Ltd's Deferred Income Tax amounts to 128.9m CNY.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 3Y
355%

Over the last year, the Deferred Income Tax growth was 3%. The average annual Deferred Income Tax growth rates for Shijiazhuang Yiling Pharmaceutical Co Ltd have been 355% over the past three years .

Back to Top